002020 京新药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)7.20111.61313.23513.95417.155
总资产报酬率 ROA (%)4.8898.0649.52210.03111.568
投入资产回报率 ROIC (%)6.22010.13011.70812.39214.788

边际利润分析
销售毛利率 (%)51.57450.57353.27555.47060.918
营业利润率 (%)22.14817.85720.01720.13723.492
息税前利润/营业总收入 (%)20.62716.36017.93719.09523.215
净利润/营业总收入 (%)18.87815.59017.66817.82620.053

收益指标分析
经营活动净收益/利润总额(%)86.28889.23292.62789.35068.261
价值变动净收益/利润总额(%)0.1506.1035.7807.91825.186
营业外收支净额/利润总额(%)0.823-0.850-0.8400.212-0.844

偿债能力分析
流动比率 (X)1.2411.6161.8072.3162.020
速动比率 (X)0.9511.3021.3811.8391.697
资产负债率 (%)32.82130.63129.75325.1690.306
带息债务/全部投入资本 (%)9.2936.4526.8795.5018.866
股东权益/带息债务 (%)916.6761,358.4101,261.6771,641.567981.332
股东权益/负债合计 (%)203.651225.326234.920295.028225.984
利息保障倍数 (X)-12.097-12.154-9.375-17.614-289.594

营运能力分析
应收账款周转天数 (天)54.15947.07944.51841.28841.070
存货周转天数 (天)116.892129.902147.920137.414129.652